Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)
Meeting – April 9, 2025 @ 4:00pm
at the
Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Haymore, Chairman:

1. **Call to Order**

A. Roll Call – Dr. Wilcox

DUR Board Members:

Mr. Kenneth Foster –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Bret Haymore –	participating in person
Dr. Craig Kupiec –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Beth Walton –	participating in person
Dr. Jennifer Weakley –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:
https://oklahoma.zoom.us/webinar/register/WN_94lCoSe9Ty2msgsLMqg2Ww
After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:
Dial: +1-602-753-0140 or +1-669-219-2599
Webinar ID: 958 2294 2095
Passcode: 65079339

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Haymore, Chairman:

2. **Public Comment Forum**
   A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Haymore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
   A. March 12, 2025 DUR Board Meeting Minutes
   B. March 12, 2025 DUR Board Recommendations Memorandum
   C. Correspondence

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

4. **Update on Medication Coverage Authorization Unit – See Appendix B**
   A. Pharmacy Help Desk Activity for March 2025
   B. Medication Coverage Activity for March 2025

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

5. **Spring Pipeline Update – See Appendix C**
   A. Spring Pipeline Update

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

6. **Action Item – Vote to Prior Authorize Pantoprazole in 0.9% Sodium Chloride (NaCl) for Intravenous (IV) Injection and Update the Approval Criteria for the Anti-Ulcer Medications – See Appendix D**
   A. Market News and Updates
   B. College of Pharmacy Recommendations

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

7. **Action Item – Vote to Prior Authorize Entresto® Sprinkle (Sacubitril/Valsartan Oral Pellets) and Update the Approval Criteria for the Heart Failure Medications – See Appendix E**
   A. Market News and Updates
   B. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

8. **Action Item – Vote to Prior Authorize Symbravo® (Meloxicam/Rizatriptan) and Update the Approval Criteria for the Anti-Migraine Medications – See Appendix F**
   A. Market News and Updates
   B. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

9. **Action Item – Vote to Prior Authorize Ctexli™ (Chenodiol), Iqirvo® (Elafibranor) and Livdelzi® (Seladelpar) and Update the Approval Criteria for the Cholestatic Liver Disease Medications – See Appendix G**
   A. Market News and Updates
   B. Product Summaries
   C. College of Pharmacy Recommendations

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

10. **Action Item – Vote to Prior Authorize Kebilidi™ (Eladocagene Exuparvovec-tneq) – See Appendix H**
    A. Market News and Updates
    B. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

11. **Action Item – Vote to Prior Authorize Crenessity™ (Crinecerfont) – See Appendix I**
    A. Market News and Updates
    B. College of Pharmacy Recommendations

Items to be presented by Dr. Sinko, Dr. Haymore, Chairman:

12. **Action Item – Vote to Prior Authorize Authorize Aucatzyl® (Obecabtagene Autoleucel), Danziten™ (Nilotinib), Grafapex™ (Treosulfan), Revuforj® (Revumenib), and Rytelo™ (Imetelstat) and Update the Approval Criteria for the Leukemia and Lymphoma Medications– See Appendix J**
    A. Market News and Updates
    B. Product Summaries
    C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

13. **Action Item – Annual Review of Topical Acne, Psoriasis, and Rosacea Products – See Appendix K**
    A. Current Prior Authorization Criteria
    B. Utilization of Topical Acne, Psoriasis, and Rosacea Products
    C. Prior Authorization of Topical Acne, Psoriasis, and Rosacea Products
    D. Market News and Updates
    E. College of Pharmacy Recommendations
    F. Utilization Details of Topical Acne, Psoriasis, and Rosacea Products

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

14. **Action Item – Annual Review of Molluscum Contagiosum Medications – See Appendix L**
    A. Current Prior Authorization Criteria
    B. Utilization of Molluscum Contagiosum Medications
    C. Prior Authorization of Molluscum Contagiosum Medications
    D. Market News and Updates
    E. College of Pharmacy Recommendations
    F. Utilization Details of Molluscum Contagiosum Medications

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

15. **Action Item – Annual Review of Growth Hormone Products and Voxzogo® (Vosoritide) – See Appendix M**
    A. Current Prior Authorization Criteria
    B. Utilization of Growth Hormone Products and Voxzogo® (Vosoritide)
    C. Prior Authorization of Growth Hormone Products and Voxzogo® (Vosoritide)
    D. Market News and Updates
    E. College of Pharmacy Recommendations
    F. Utilization Details of Growth Hormone Products and Voxzogo® (Vosoritide)

Items to be presented by Dr. Ratterman, Dr. Haymore, Chairman:

16. **Annual Review of Hemophilia Medications Medications and 30-Day Notice to Prior Authorize Alhemo® (Concizumab-mtci), Beqvez™ (Fidanacogene Elaparvovec), Hympavzi™ (Marstacimab-hncq), and Qfitlia™ (Fitusiran) – See Appendix N**
    A. Current Prior Authorization Criteria
    B. Utilization of Hemophilia Medications
    C. Prior Authorization of Hemophilia Medications
    D. Market News and Updates
    E. Product Summaries
    F. Oklahoma Health Care Authority Recommendations
    G. Utilization Details of Hemophilia Medications

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

17. **Annual Review of Muscular Dystrophy Medications and 30-Day Notice to Prior Authorize Agamree® (Vamorolone) and Duvyzat™ (Givinostat) – See Appendix O**
    A. Current Prior Authorization Criteria
    B. Utilization of Muscular Dystrophy Medications
    C. Prior Authorization of Muscular Dystrophy Medications
    D. Market News and Updates
    E. Product Summaries
    F. College of Pharmacy Recommendations
    G. Utilization Details of Muscular Dystrophy Medications

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

18. **Annual Review of Multiple Sclerosis (MS) Medications and 30-Day Notice to Prior Authorize Ocrevus Zunovo™ (Ocrelizumab/Hyaluronidase-ocsq) – See Appendix P**
    A. Current Prior Authorization Criteria
    B. Utilization of MS Medications
    C. Prior Authorization of MS Medications
    D. Market News and Updates
    E. Ocrevus Zunovo™ (Ocrelizumab/Hyaluronidase-ocsq) Product Summary
    F. College of Pharmacy Recommendations
    G. Utilization Details of MS Medications

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

19. **Annual Review of Granulocyte Colony-Stimulating Factors (G-CSFs) and Stem Cell Mobilizers and 30-Day Notice to Prior Authorize Xolremdi® (Mavorixafor) – See Appendix Q**
    A. Current Prior Authorization Criteria
    B. Utilization of G-CSFs and Stem Cell Mobilizers
    C. Prior Authorization of G-CSFs and Stem Cell Mobilizers
    D. Market News and Updates
    E. College of Pharmacy Recommendations
    F. Utilization Details of G-CSFs and Stem Cell Mobilizers

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

20. **30-Day Notice to Prior Authorize Journavx™ (Suzetrigine) – See Appendix R**
    A. Journavx™ (Suzetrigine) Product Summary
    B. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

21. **Annual Review of Thrombocytopenia Medications and 30-Day Notice to Prior Authorize Adzynma (ADAMTS13, Recombinant-krhn) and Alvaiz® (Eltrombopag) – See Appendix S**
    A. Current Prior Authorization Criteria
    B. Utilization of Thrombocytopenia Medications
    C. Prior Authorization of Thrombocytopenia Medications
    D. Market News and Updates
    E. Product Summaries
    F. College of Pharmacy Recommendations
    G. Utilization Details of Thrombocytopenia Medications

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

22. **U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix T**

Items to be presented by Dr. Adams, Dr. Haymore, Chairman:

23. **Future Business* (Upcoming Product and Class Reviews)**
    A. Anti-Diabetic Medications and Kerendia® (Finerenone)
    B. Attention-Deficit/Hyperactivity Disorder (ADHD) and Narcolepsy Medications
    C. Botulinum Toxins
    D. Parkinson's Disease Medications
    E. Spinal Muscular Atrophy (SMA) Medications

    *Future product and class reviews subject to change.

24. **Adjournment**

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.

NOTE: Oklahoma Medicaid transitioned from a fee-for-service (FFS) pharmacy benefit to a managed care pharmacy benefit for most members on April 1, 2024. At that time, the majority of SoonerCare members were transitioned to one of the three managed care SoonerSelect plans: Aetna, Humana, or Oklahoma Complete Health. SoonerSelect data has been provided to the College of Pharmacy and has been used in analyses throughout this DUR Board meeting packet. The data included in this DUR Board meeting packet combines FFS and managed care utilization data. The managed care utilization and prior authorization (PA) data reported in this packet is based solely on the data provided by the SoonerSelect plans.